Trial Profile
A Single-center, Randomized, Double-blind, Placebo-controlled, 6 Month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Ibudilast (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms IBU-ALS-1201
- Sponsors MediciNova
- 04 Dec 2019 According to a MediciNova media release, results of additional analyses from the study will be presented at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) 2019.
- 04 Dec 2019 Results from additional analyses presented in a MediciNova media release.
- 29 Jul 2019 According to a MediciNova media release, data from the study will be presented at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease).